Isatuximab for relapsed / refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study

Share "Isatuximab for relapsed / refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study"

N/A

Protected

Studieår: 2022

Info

Protected

Academic year: 2022

Share "Isatuximab for relapsed / refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study"

Copied!

Fulltekst

Referanser

RELATERTE DOKUMENTER

$OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma$